BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/15/2024 9:49:52 AM | Browse: 373 | Download: 965
 |
Received |
|
2023-11-18 17:59 |
|
Peer-Review Started |
|
2023-11-18 18:00 |
|
First Decision by Editorial Office Director |
|
2023-12-08 02:42 |
|
Return for Revision |
|
2023-12-08 02:42 |
|
Revised |
|
2023-12-16 23:03 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-01-03 03:29 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-01-25 05:37 |
|
Articles in Press |
|
2024-01-25 05:37 |
|
Edit the Manuscript by Language Editor |
|
2024-01-31 23:11 |
|
Typeset the Manuscript |
|
2024-03-07 07:56 |
|
Publish the Manuscript Online |
|
2024-03-15 09:49 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Roles of fibroblast growth factors in the treatment of diabetes
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Chun-Ye Zhang and Ming Yang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ming Yang, DVM, PhD, Research Assistant Professor, Department of Surgery, University of Missouri, Room 2203, NextGen Precision Building, 1030 Hitt Street, Columbia, MO 65212, United States. yangmin@health.missouri.edu |
| Key Words |
Fibroblast growth factors; Type 1 diabetes; Type 2 diabetes; Metabolic disorders; Treatment; Clinical trials |
| Core Tip |
Diabetes affects about 422 million people worldwide, causing 1.5 million deaths each year. However, the incidence of diabetes is increasing, including both type 1 and type 2 diabetes. New therapies for diabetes are needed to prevent this increasing incidence. The fibroblast growth factor (FGF) family members play important roles in many metabolic disorders, including diabetes. To date, a total of 23 family members (FGF1-23) have been found in humans. Some FGFs, such as FGF-15, FGF-19, and FGF-21, have anti-diabetic functions in pre-clinical studies, and they are under investigation in clinical trials for examining the therapeutic effects in patients. |
| Publish Date |
2024-03-15 09:49 |
| Citation |
Zhang CY, Yang M. Roles of fibroblast growth factors in the treatment of diabetes. World J Diabetes 2024; 15(3): 392-402 |
| URL |
https://www.wjgnet.com/1948-9358/full/v15/i3/392.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v15.i3.392 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
